Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Therapeutic Modalities

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.
Read More
Therapeutic Modalities

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.
Read More
Therapeutic Modalities

Zika Virus Tested as an Effective Oncolytic Agent for Glioblastoma in In Vitro Models

More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro.
Read More
Therapeutic Modalities

Post-Event Proceedings – Immuno 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Immuno 2023.
Read More
Therapeutic Modalities

In Vivo Models Show Survival Promise for Zika Oncolytic Viral Therapy for Neuroblastoma

One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus.
Read More
Therapeutic Modalities

Experiments Link Gut Microbiome and Graft-versus-Host Disease

Modulating the gut microbiome may be a key to preventing GvHD and stopping relapse.
Read More
Therapeutic Modalities

UPenn Medicine Presents Promising Phase I CAR T Trial with Novel Binding Mechanism

The CAR T therapy targets CD19 closer to the cell membrane and has demonstrated remarkable efficacy in its Phase I clinical trial.
Read More
Therapeutic Modalities

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
Read More
Therapeutic Modalities

Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences

Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
Read More
Therapeutic Modalities

Monitoring Cell – Attachment and Tightjunctions in the Same Assay

Nanion Technologies GmbH, Munich. University of Regensburg, Regensburg.
Read More
Therapeutic Modalities

SomaScan Panels

Big Insights. Targeted Data. Consistent Results.
Read More
Therapeutic Modalities

SomaScan®Assay v4.1

The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness.
Read More
Therapeutic Modalities

SomaSignal® Tests

Multiple clinical assessments from a single blood draw.
Read More
Therapeutic Modalities

SomaScan Assay

A proteomics platform driving pioneering discoveries
Read More
Therapeutic Modalities

Enfortumab Vedotin/Pembrolizumab Combo Beats Chemo in Phase III Breakthrough

The Phase III clinical trial, named EV-302/KEYNOTE-A39, has unveiled that immunotherapy can outperform chemo in urothelial bladder cancer for the first time.
Read More
Therapeutic Modalities

Compugen: Exploring New Pathways and Combinations in Immunotherapy

Looking at new pathways for ICIs and Compugen's triple pathway hypothesis may be paving the way for next-generation cancer immunotherapy.
Read More
Therapeutic Modalities

European Commission Approves Genmab’s Subcutaneous Bispecific Antibody Tepkinly

The approval follows positive results from Genmab's 'Epcore' phase I/II clinical trial.
Read More
Therapeutic Modalities

NK Cell Therapies: Development, Application, and Challenges

Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery.
Read More
Therapeutic Modalities

Another Partnership from Takeda and F-Star Therapeutics to Look for Antibody-Based Therapies

The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star.
Read More
Therapeutic Modalities

Immune Cell Types: Their Opportunities for Therapeutic Use in Oncology

An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies.
Read More
Therapeutic Modalities

William Coley, the Father of Cancer Immunotherapy and His Legacy

Despite facing criticism in his time, his work laid the foundation for modern immuno-oncology and his legacy continues through the Cancer Research Institute.
Read More
Therapeutic Modalities

AstraZeneca and Daiichi Sankyo Share Results of IO Combination Therapy in Ib Clinical Trial

Preliminary results from phase Ib clinical trial, TROPION-Lung02, evaluating the antibody drug conjugate datopotamab deruxtecan in combination with pembrolizumab.
Read More
Therapeutic Modalities

Monoclonal Antibodies: Guided Missiles in the Battle Against Cancer and More

Monoclonal antibodies (mAbs) have emerged as highly promising and versatile treatments for various diseases, particularly cancer.
Read More
Therapeutic Modalities

Identifying highly potent TNF-?-secreting T cells from blood samples in 7 hours using the Xdrop® double-emulsion droplet-based workflow

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop workflow reveals highly potent TNF-?-secreting T cells in a human blood sample.
Read More
Therapeutic Modalities

Xdrop® Encapsulate cells, DNA, and more with this benchtop instrument

Xdrop is a unique, user-friendly microfluidics instrument for preparing living mammalian or microbial cells, organelles, DNA, or other biological material for high-resolution downstream analyses.
Read More
Therapeutic Modalities

Rapidly quantifying active killer cells using an Xdrop® single-cell format assay based on double-emulsion droplets

Bulk assays of killer cell activity mask the heterogeneity of the individual cells‘ actual cytotoxicity. This Xdrop single-cell format assay for quantifying natural killer cells reveals the active cells and enables their retrieval and expansion.
Read More
Therapeutic Modalities

Revealing and retrieving highly potent IFN-? secretors using an Xdrop® single-cell format workflow based on double-emulsion droplets

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop single-cell format workflow for IFN-? secretion assessment reveals these highly potent individual cells, enabling their retrieval and expansion.
Read More
Therapeutic Modalities

Quantifying individual cells that secrete IFN-?, TNF-?, or both cytokines in a single-cell, drop®-based workflow

This Xdrop workflow enables rapid, multiplex quantification of the individual immune cells in a population that are secreting one or more cytokines. The results for single-cell format multiplex and singleplex assay concurred and were reproducible.
Read More
Therapeutic Modalities

Cancer Vaccines: Analysing the Resurgence

Looking at the past, present, and future of cancer vaccines. What are the reasons for past failings? And what's the next step for their development?
Read More
Therapeutic Modalities

App Note: CAR-T: A Promising Cell Therapy for Cancer Treatment

This application note by Sino Biological explores the key steps involved in CAR-T production to provide insights into the challenges that may impede successful CAR-T therapy.
Read More
Therapeutic Modalities

NK Cell Therapies and Their Promising Possibilities

Considering the potential of natural killer (NK) cells as immunotherapies for cancer treatment and the various methods being utilised to overcome cancer cells' resistance to NK cells.
Read More
Therapeutic Modalities

Axion Biosystems: In vitro Potency Assays for Immune Cell-Mediated Killing with the Maestro Z

Immunotherapy harnesses the power of the innate and adaptive immune system in various ways to seek out and attack cancer.
Read More
Therapeutic Modalities

Axion Biosystems: Quantifying NK-mediated Cytolysis of Glioblastoma in vitro with Maestro Z

Immunotherapy aims to harness and enhance the body’s immune system to fight cancer.
Read More
Therapeutic Modalities

GD2 CAR-T cells engineered using retroviral transduction or CRISPR editing exhibit strong cytolytic potency against glioma stem cells

Axion BioSystems’ Maestro Z platform offers impedance-based cell analysis for real-time, label-free monitoring of cell viability, morphology, cytolysis, and signaling.
Read More
Therapeutic Modalities

Axion Biosystems: Antibody-dependent Cellular Cytotoxicity of Natural Killer Cells

Trastuzumab promotes natural killer cell activation through antibody-dependent cellular cytotoxicity (ADCC).
Read More
Therapeutic Modalities

Axion Biosystems: CAR T Cell Potency Assessment with 3D Cancer Spheroid Models

The solid tumor microenvironment poses a significant challenge to immune therapies like CART cells.
Read More
Therapeutic Modalities

Targeting oxMIF To Develop Novel Biotherapeutics

An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.
Read More
Therapeutic Modalities

Chipscreen Licences Eucure Biopharma's Keytruda Competitor for Greater China

The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.
Read More
Therapeutic Modalities

Therapy In the Spotlight: CAR T Cell Therapy—Significant Approvals and Regulatory Concerns

What are the regulatory considerations for CAR T cell therapy, and what's next for the approach?
Read More
Therapeutic Modalities

Novel TNF Superfamily Antagonists for Cancer & Autoimmunity

An interview with Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics
Read More
Therapeutic Modalities

Antibody Discovery by Single B Cell Screening on Beacon®

On-Demand Webinar featuring Dr Amy Sheng, Technical Account Manager at Sino Biological
Read More
Therapeutic Modalities

Experts Discuss Developing Oncolytic Virus Immunotherapy

Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field
Read More
Therapeutic Modalities

What are the Key Challenges in Developing Bispecific Antibodies for Cancer Immunotherapy?

Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?
Read More
Therapeutic Modalities

Viral Immunotherapy: A New Approach Towards Tackling Solid Tumours

As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.
Read More
Therapeutic Modalities

T Cell Enhancers: Conditional Activation for a Safe and Durable Response

Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.
Read More
Therapeutic Modalities

Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape

Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.
Read More
Therapeutic Modalities

Biologics Solutions: Plasmid DNA - Charles River

Read More
Therapeutic Modalities

Biologics Solutions: Viral Vectors - Charles River

Read More
Therapeutic Modalities

Biologics Solutions: Cell Therapy - Charles River

Read More
Therapeutic Modalities

Biologics Solutions Facilities and Capabilities

Read More
Therapeutic Modalities

Immunology Services by Cell Type - Charles River

Read More
Therapeutic Modalities

The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology

The targeted cancer therapy has made recent clinical and market breakthroughs, but what are the next hurdles for ADCs?
Read More
Therapeutic Modalities

Immuno Oncology Investigations: The NKG2D Pathway, Diagnostic Biomarker, and Allogenic CAR Ts

Cell UK 2021 hosts experts in cell and immunotherapy working towards new diagnostic tools and therapies.
Read More
Therapeutic Modalities

Express Your Cells: Enhancing T Cell Function with Small Molecule HPK1 Inhibitors

Inhibiting the HPK1 pathway can enhance the cancer killing function of T lymphocytes. RAPT Therapeutics showcases a series of small molecules to do this.
Read More
Therapeutic Modalities

iNKT Cells and Their Applications in Immuno-Oncology

The applications of iNKT cells as oncological therapeutics and remedial treatments are almost astoundingly diverse. Their capacity for moderation subject to their intended use makes them suited to a variety of therapeutic functions and applications.
Read More
Therapeutic Modalities

Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.
Read More
Therapeutic Modalities

Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors

Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.
Read More
Therapeutic Modalities

Microbiome Solutions to Immuno-Oncology Problems

Investigating the role of the microbiota in checkpoint inhibitor response.
Read More
Therapeutic Modalities

Targeting Solid Tumours With TCR Guided NK Cells

Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy
Read More
Therapeutic Modalities

Are Genomic Technologies the Key to Unlock Precision Immunotherapies?

The power of the genome has enormous implications for immunotherapy
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno